Compare KPLT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPLT | AYTU |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 25.7M |
| IPO Year | N/A | 2015 |
| Metric | KPLT | AYTU |
|---|---|---|
| Price | $5.89 | $2.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $9.33 |
| AVG Volume (30 Days) | 19.2K | ★ 59.3K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $15.48 | $44.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $5.50 | $0.95 |
| 52 Week High | $24.15 | $3.07 |
| Indicator | KPLT | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 36.50 | 63.73 |
| Support Level | $5.50 | $2.14 |
| Resistance Level | $6.92 | $2.82 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 18.13 | 96.43 |
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.